Evidence map›Paper›PMID 42157924›Full record

ArticleInternational journal of biological sciences2026

Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8

Zhiran Zhai, Jumin Huang, Jiayue Qiu, Yuwei Wang, Jin Liao, Chun Xie, Jiahui Xu, Zebo Jiang, Yajia Xie, Wenkang Ren and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhiran ZhaiSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Jumin HuangCancer Center, Faculty of Health Sciences, Ministry of Education (MOE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China.
Jiayue QiuSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Yuwei WangCollege of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
Jin LiaoCancer Center, Faculty of Health Sciences, Ministry of Education (MOE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China.
Chun XieCancer Center, Faculty of Health Sciences, Ministry of Education (MOE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China.
Jiahui XuCancer Center, Faculty of Health Sciences, Ministry of Education (MOE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China.
Zebo JiangSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Yajia XieSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Wenkang RenSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Yizhong ZhangZhuhai UM Science & Technology Research Institute, University of Macau, Hengqin, Macau SAR, China.
Haoxin YanZhuhai UM Science & Technology Research Institute, University of Macau, Hengqin, Macau SAR, China.
Meifang WangDepartment of Respiratory and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Chen HuangSchool of Pharmacy, Faculty of Chinese Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Taipa, Macau, China.
Elaine Lai Han LeungCancer Center, Faculty of Health Sciences, Ministry of Education (MOE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer has the highest mortality rate globally, yet the effective treatment options remain limited. Although short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate are known to modulate immune response and improve the efficacy of cancer therapy, the role of valerate in non-small cell lung cancer (NSCLC) remains unexplored. This study identifies valerate as a biased ligand for GABA

Indexed as

Activating Transcription Factor 4Carcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesChemokine CXCL13Lung NeoplasmsNF-E2-Related Factor 2AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceTumor MicroenvironmentActivating Transcription Factor 4Chemokine CXCL13CXCL13 protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2anti-tumor immunityGABBR1non-small cell lung cancervalerate

Identifiers

PMID42157924
PMCPMC13181851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.